News
ARQT
25.08
-1.07%
-0.27
Top Arcutis Executive Makes Notable Move With Latest Stock Sale
TipRanks · 20h ago
Arcutis-Backed Phase 3 ZORYVE Foam Study Targets Growth in Seborrheic Dermatitis
TipRanks · 1d ago
Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis Patients
Benzinga · 2d ago
Arcutis says Health Canada approves Zoryve cream 0.05% for children with AD
TipRanks · 2d ago
Arcutis Biotherapeutics (ARQT) Could Be 28% Undervalued As Profit And Guidance Improve
Simply Wall St · 3d ago
Weekly Report: what happened at ARQT last week (0810-0814)?
Weekly Report · 5d ago
Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action?
Simply Wall St · 08/15 06:22
Arcutis Targets Real-World Itch Relief Data With New Phase 4 Roflumilast Study
TipRanks · 08/13 16:31
Arcutis (ARQT) Q2 2026 Earnings Call Transcript
The Motley Fool · 08/12 21:28
Arcutis Biotherapeutics Earnings Call Highlights Growth Momentum
TipRanks · 08/12 00:28
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)
TipRanks · 08/11 08:10
Weekly Report: what happened at ARQT last week (0803-0807)?
Weekly Report · 08/10 10:06
Arcutis Biotherapeutics (ARQT) Could Be 31% Undervalued Following Profit And Higher Guidance
Simply Wall St · 08/09 16:26
Arcutis Swings To Q2 Profit As ZORYVE Sales Grow; Raises FY26 Product Sales View
NASDAQ · 08/07 08:08
Arcutis Biotherapeutics (ARQT) Stock Profit Turn Faces ZORYVE Concentration Question
Simply Wall St · 08/07 01:37
Arcutis Biotherapeutics Price Target Raised to $38.00/Share From $34.00 by Morgan Stanley
Dow Jones · 08/06 17:29
Arcutis Biotherapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 08/06 17:29
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38
Benzinga · 08/06 17:19
Did Profitability, Higher 2026 Guidance, and New Commercial Leadership Just Recast Arcutis Biotherapeutics' (ARQT) Investment Narrative?
Simply Wall St · 08/06 15:40
Arcutis Biotherapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 08/06 13:38
More
Webull provides a variety of real-time ARQT stock news. You can receive the latest news about Arcutis Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.